Vanda Pharmaceuticals, Inc. (VNDA) Posts Wider than Expected Q4 Loss
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $5.43 +1.69%
EPS Growth %: -60.5%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -60.5%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q4 EPS of ($0.20), $0.01 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $8.2 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
- JPMorgan Downgrades Woolworths Holdings Ltd (WHL:SJ) to Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
